Tekla Life Sciences Investors
NYSE:HQLAsset Management
+$0.11 today
- Market cap
- $585.96M
- Beta
- 0.73
- P/E (TTM)
- 2.8
- EPS (TTM)
- $6.52
- Dividend yield
- 11.35%
Volume 0.12M
Average 0.11M
HQL EBITDA Margin
EBITDA as a percentage of revenue.
Tekla Life Sciences InvestorsNYSE: HQL
EBITDA Margin · Q2 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to 135.9%
EBITDA Margin was 135.9% in Q2 FY2026, up 395.5 pp from a year earlier. Over 3 fiscal years it widened by 418.0 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 99.1%
- Year-over-year change
- -1.5pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 99.1% | -1.5pp |
| FY2024 | 2024-09-30 | 100.6% | -26.2pp |
| FY2023 | 2023-09-30 | 126.8% | +445.7pp |
| FY2022 | 2022-09-30 | -318.9% | -471.5pp |
| FY2021 | 2021-09-30 | 152.5% | — |
EBITDA Margin vs competitors
How HQL compares with its peers on the latest reported figures
- HQL's FY2025 EBITDA Margin of 99.1% is the 3rd highest of the 10 companies compared; the peer median is 48.4%.
- Its year-over-year change of -1.5 pp is the 5th highest of 10, against a peer median of -2.8 pp.
- Over three fiscal years its change of +418.0 pp compares with a peer median of +31.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| FY2025 | 135.3% | +38.0 pp | +293.4 pp | |
| LTM Mar 2026 | 118.5% | +45.1 pp | +217.4 pp | |
| FY2025 | 99.1% | -1.5 pp | +418.0 pp | |
| LTM Mar 2026 | 96.3% | +47.6 pp | +113.3 pp | |
| LTM Mar 2026 | 71.5% | -9.9 pp | -27.6 pp | |
| LTM Jun 2025 | 48.4% | -37.8 pp | +31.5 pp | |
| LTM Mar 2026 | 40.9% | -2.8 pp | +34.3 pp | |
| LTM Mar 2026 | 18.4% | +32.8 pp | -15.7 pp | |
| LTM Dec 2025 | -50.8% | -50.5 pp | -204.8 pp | |
| LTM Mar 2026 | -388.5% | -268.6 pp | -79.5 pp | |
| Peer median (excluding HQL) | 48.4% | -2.8 pp | +31.5 pp | |
Competitors are the stored peer set for HQL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 45.02M | 31.86M | 39.39M | 86.69M | 86.39M |
| Cost of Revenue | 6.08M | 5.55M | 5.24M | 5.36M | 4.97M |
| Gross Profit | 38.95M | 26.31M | 18.28M | 86.69M | 86.39M |
| Gross Margin | 86.5% | 82.6% | 46.4% | 100.0% | 100.0% |
| Research & Development | 0 | (3) | 0 | 0 | 0 |
| Selling, General & Admin | 844.02K | 1.08M | 903.14K | 1.33M | 743.17K |
| Operating Expenses | 1.16M | 1.35M | 1.17M | 1.39M | 791.57K |
| Depreciation & Amortization | 4.14M | 2.99M | 27.6M | 1.92M | 0 |
| EBITDA | 68.68M | (101.62M) | 49.95M | 87.22M | 85.59M |
| EBITDA Margin | 152.5% | -318.9% | 126.8% | 100.6% | 99.1% |
| Operating Income | 64.53M | (104.6M) | (5.24M) | 85.3M | 85.59M |
| Operating Margin | 143.3% | -328.3% | -13.3% | 98.4% | 99.1% |
| Interest Income | 0 | 50.09K | 204.45K | 1.04M | 349.84K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (7.83K) | 2.42K | 27.6M | 87.22M | 0 |
| Income Before Tax | 64.53M | (104.6M) | 22.35M | 85.3M | 85.59M |
| Pre-Tax Margin | 143.3% | -328.3% | 56.8% | 98.4% | 99.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | 64.53M | (104.6M) | 22.35M | 85.3M | 85.59M |
| Net Margin | 143.3% | -328.3% | 56.8% | 98.4% | 99.1% |
| EPS (Basic) | 2.66 | (4.07) | 0.79 | 3.04 | 2.96 |
| EPS (Diluted) | 2.66 | (4.07) | 0.79 | 3.04 | 2.96 |
| Weighted Avg Shares | 24.26M | 25.68M | 28.29M | 28.06M | 28.87M |
| Weighted Avg Shares (Diluted) | 24.26M | 25.68M | 28.29M | 28.06M | 28.87M |
Tekla Life Sciences Investors
NYSE:HQL
Intrinsic Alpha fair value
Locked
Current Price
$19.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.